Clinical neurology and neurosurgery · 2026
Sex differences in outcomes of dural arteriovenous fistula treatment in Japan: Analysis of the Japanese Registry of Neuroendovascular Therapy (JR-NET 4).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shindo Koichiro, Uchida Kazutaka, Shirakawa Manabu, Sakakibara Fumihiro, Tatebayashi Kotaro, Fujiwara Satoru, Iihara Koji, Imamura Hirotoshi, Ishii Akira, Matsumaru Yuji, Sakai Chiaki, Satow Tetsu, Yoshimura Shinichi, Sakai Nobuyuki, JR-NET4 Study Group
Аннотация
OBJECTIVE: Sex differences in outcomes after endovascular treatment (EVT) for dural arteriovenous fistula (dAVF) remain unclear. This study aimed to compare 30-day complications and outcomes between women and men using data from the Japanese Registry of Neuroendovascular Therapy registry in Japan.
METHODS: We analyzed data from a nationwide retrospective registry (2015-2019), comparing outcomes between women and men who underwent EVT for dAVFs. The primary outcome was worsening of modified Rankin Scale (mRS) score ≥ 2 at 30 days after EVT. Secondary outcomes included 30-day morbidity, defined as any procedure-related complication such as intracranial hemorrhage or ischemic stroke, favorable outcome (mRS 0-2), and mortality.
RESULTS: Among 3156 patients (1561 women, 1532 men; mean age 68.8 vs. 63.8 years, p < 0.0001), dAVF location and preprocedural symptoms differed significantly by sex. Worsening of mRS ≥ 2 occurred in 7.1% of women and 11.6% of men (adjusted odds ratio [aOR] 0.84; 95% CI 0.64-1.11; p = 0.23). Thirty-day morbidity was similar (5.3% vs. 5.4%; aOR 1.07; 95% CI 0.77-1.48). Hemorrhagic complications were more frequent in women (1.9% vs. 1.3%; aOR 1.93; 95% CI 1.07-3.50). Favorable outcomes were slightly more common in women (90.1% vs. 86.2%), and 30-day mortality was low in both groups (<1%).
CONCLUSIONS: This large retrospective registry study found significant sex-based differences in dAVF location but no significant differences in worsening of mRS ≥ 2, 30-day morbidity or the rate of patients achieving a favorable mRS score at 30 days after EVT.
METHODS: We analyzed data from a nationwide retrospective registry (2015-2019), comparing outcomes between women and men who underwent EVT for dAVFs. The primary outcome was worsening of modified Rankin Scale (mRS) score ≥ 2 at 30 days after EVT. Secondary outcomes included 30-day morbidity, defined as any procedure-related complication such as intracranial hemorrhage or ischemic stroke, favorable outcome (mRS 0-2), and mortality.
RESULTS: Among 3156 patients (1561 women, 1532 men; mean age 68.8 vs. 63.8 years, p < 0.0001), dAVF location and preprocedural symptoms differed significantly by sex. Worsening of mRS ≥ 2 occurred in 7.1% of women and 11.6% of men (adjusted odds ratio [aOR] 0.84; 95% CI 0.64-1.11; p = 0.23). Thirty-day morbidity was similar (5.3% vs. 5.4%; aOR 1.07; 95% CI 0.77-1.48). Hemorrhagic complications were more frequent in women (1.9% vs. 1.3%; aOR 1.93; 95% CI 1.07-3.50). Favorable outcomes were slightly more common in women (90.1% vs. 86.2%), and 30-day mortality was low in both groups (<1%).
CONCLUSIONS: This large retrospective registry study found significant sex-based differences in dAVF location but no significant differences in worsening of mRS ≥ 2, 30-day morbidity or the rate of patients achieving a favorable mRS score at 30 days after EVT.